New pre-clinical and clinical data from studies of nitric oxide delivery systems from GeNO will be presented at both the American College of Cardiology’s Annual Scientific Session and the American Thoracic Society International Conference, according to the company.
“The data to be presented at these meetings provide important new insights into the clinical utility of ultrapure, inhaled nitric oxide delivered by GeNO’s nitric oxide delivery system,” said David Fine, PhD, the CEO of GeNO.
“Nitric Oxide Treatment of Right Ventricular (RV) Failure Associated with the Use of a Left Ventricular Assist Device (LVAD) and Hypoxemia-induced Pulmonary Hypertension” will be presented at the American College of Cardiology 62nd Annual Scientific Session in San Francisco, CA on March 11.
The presentation will include pre-clinical data from a study showing GeNO’s inhaled nitric oxide delivery system decreased pulmonary vascular resistance (PVR) and RV distension, increased RV ejection, and increased the maximum achievable LVAD speed and flow in a mammal model with LVAD associated RV failure and hypoxemia induced pulmonary hypertension.
On May 20, “Ambulatory System for the Delivery of Nitric Oxide (NO) Derived from Liquid Dinitrogen Tetroxide (N2O4)” will be presented at the American Thoracic Society International Conference in Philadelphia. This pre-clinical data shows a novel approach for the delivery of inhaled nitric oxide to a mammal that, for the first time, uses a small volume of liquid rather than cylinders of compressed gas.
Robert Roscigno, PhD, Executive Vice President of Clinical Development for GeNO, stressed that “as we advance this investigational product into late stage clinical trials for various forms of Pulmonary Hypertension, additional therapeutic options are still needed. These data support further clinical development of GeNO’s technologies for use by patients in need of acute and chronic Pulmonary Hypertension therapies.”